Recommendations pertaining to the use of viral vaccines: Influenza, 2005 by Health, Deaprtment of
February 2005, Vol. 95, No. 2  SAMJ
SAMJ FORUM
104
Recommended vaccine formulation
The following strains have been recommended by the World
Health Organization for the 2005 southern hemisphere
influenza season: 
• A/New Caledonia/20/99 (H1N1)-like virus
• A/Wellington/1/2004 (H3N2)-like virus
• B/Shanghai/361/2002-like virus.
The actual viral strains recommended for the vaccine for
each component are as follows: 
• IVR-139 recommended for the A/Wellington/1/2004
(H3N2)-like strain
• IVR-116 recommended for the A/New Caledonia/20/99
(H1N1)-like strain.
• B/Jiangsu/10/2003 recommended for the B/Shanghai/
361/2002-like strain
Vaccines should contain 15 µg of each haemagglutinin
antigen in each 0.5 ml dose.
Indications
1. Persons (adults or children) who are at high risk for
influenza and its complications because of underlying
medical conditions and who are receiving regular
medical care for conditions such as chronic pulmonary
and cardiac disease, chronic renal diseases, diabetes
mellitus and similar metabolic disorders, and individuals
who are immunosuppressed (including HIV-infected
persons with CD4 counts above 200/µl).
2. Residents of old-age homes, chronic care and
rehabilitation institutions.
3. Children on long-term aspirin therapy.
4. Medical and nursing staff responsible for the care of
high-risk cases.
5. Adults and children who are family contacts of high-risk
cases.
6. All persons over the age of 65 years.
7. Women who would be in the second or third trimester of
pregnancy during the influenza season.  Pregnant
women with medical conditions placing them at risk for
influenza complications should be immunised at any
stage of pregnancy.
8. Any persons wishing to protect themselves from the risk
of contracting influenza, especially in industrial settings,
where large-scale absenteeism could cause significant
economic losses.
Dosage
• Adults: Whole or split-product or subunit vaccine — one
dose intramuscularly.
• Children (< 12 years) Split-product or subunit vaccine — 
1 dose intramuscularly.
• Children < 9 years who have never been vaccinated
should receive two doses 1 month apart. Children less
than 3 years of age should receive half the adult dose on
two occasions, 1 month apart.
Contraindications
• Persons with a history of severe hypersensitivity to eggs.
• Persons with acute febrile illnesses should preferably be
immunised after symptoms have disappeared.
• The vaccine should be avoided in the first trimester of
pregnancy unless there are specific medical indications
(see indication No. 7 above).
Timing
Vaccines should be given sufficiently early to provide
protection for the winter.  A protective antibody response
takes about 2 weeks to develop.
Chemoprophylaxis
In cases where vaccine has not been administered,
consideration should be given to the use of supplementary
chemoprophylaxis with amantadine in certain high-risk
individuals, e.g. patients with chronic lung and heart
diseases.  Amantadine should be administered in a dosage
of 200 mg daily in two divided doses for the duration of the
epidemic activity, i.e. approximately 6 -12 weeks.  The
dosage should be reduced in persons with renal disease and
persons over the age of 65 years.
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